By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

The reason is so compelling that I actually did buy the stock -- and I have no plans to sell.

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ecnoglutide, a once-weekly injectable drug licensed from Hangzhou-based Sciwind ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, ...

SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...